Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/3/16  and contains information from public web pages.

Dr. E. Shelley Hwang

Wrong Dr. E. Shelley Hwang?

Chief of Breast Surgery

Phone: (919) ***-****  HQ Phone
Duke Cancer Institute
710 W Main Street, Suite 200
Durham , North Carolina 27701
United States



  • M.D.
  • M.P.H.
23 Total References
Web References
Principal investigator E. Shelley ..., 3 Feb 2016 [cached]
Principal investigator E. Shelley Hwang, MD, chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.
"This will be a definitive clinical trial that will help set the course for future DCIS treatment," said Hwang, who has been a leading voice in the national debate calling for a more informed approach to treating DCIS. "It is based on what we are discovering about the tremendous variety we see even in one disease such as DCIS, and how we must design our future treatments to more precisely reflect those differences."
Hwang will work with co-principal investigators Alastair M. Thompson, MD, from The University of Texas MD Anderson Cancer Center and Ann H. Partridge, MD, from Dana-Farber Cancer Institute, partnering with The Alliance for Clinical Trials in Oncology.
"Anyone whose DCIS progresses would be immediately treated with standard therapy," Hwang said. "When detected early in this way, the outlook for long-term survival and even a cure is excellent."
Hwang said the study would provide data about the best candidates for active surveillance, and create a repository of imaging and cell samples to advance knowledge into the molecular biology of DCIS and what fuels or deters its growth.
The study is also designed to collaborate closely with a similar trial that was initiated last year in Europe, providing the ability to combine findings that will then strengthen the statistical conclusions globally.
"This study will provide so many answers to questions that are critical to resolve," Hwang said.
"With this analysis, we sought to ..., 22 Oct 2015 [cached]
"With this analysis, we sought to determine what treatment women selected when diagnosed with DCIS, and whether there was any impact in mortality with the different treatments," said senior author E. Shelley Hwang, MD, chief of breast surgery at the Duke Cancer Institute.
"This is an important women's health issue, and we still do not have enough data around what the best treatment is," Hwang said. "Studies like ours should be viewed as a call for well-designed clinical trials that could provide more information to better guide both doctors and patients."
Hwang and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) program in the United States to analyze more than 121,000 cases between 1991 and 2010 in which women were diagnosed with DCIS.
"One of the things we wanted to examine was what happened to these women after they were diagnosed with DCIS," Hwang said. "Overall, 9.2% of all deaths were due to breast cancer. However, the predominant cause of death was not breast cancer, but cardiovascular disease, which accounted for 33% of all deaths."
Hwang said the exception was among women younger than age 50 with DCIS, where one-third of deaths resulted from breast cancer, highlighting the importance of aggressive treatment for those patients.
"What our study shows is that we urgently need clinical trials to know whether we are doing the right thing for this group of patients," Hwang said.
Dr. Shelley Hwang, chief of ..., 27 Oct 2015 [cached]
Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C., said she also sees DCIS patients who would rather watch it than treat it. But she noted that doctors don't yet have conclusive proof that certain types of DCIS can safely go untreated.
"We need to collect the data that will allow for clear risk communication with patients so they can make their own decisions about their care," she said.
Faculty - Duke Cancer Institute, 10 July 2015 [cached]
Eun-Sil Shelley Hwang, M.D. Professor of Surgery
Faculty - Duke Cancer Institute, 10 July 2015 [cached]
Shelley Hwang, MD, MPH
Other People with the name "Hwang":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.